trending Market Intelligence /marketintelligence/en/news-insights/trending/3llDln0Q_UYxBjwBEgDffA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

ChromaDex raises $7M via private placement for international expansion

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

ChromaDex raises $7M via private placement for international expansion

ChromaDex Corp. plans to raise $7 million in gross proceeds from a private placement of common stock priced at $4.465 each.

The Irvine, Calif.-based company entered a securities purchase agreement to sell 1,567,748 of its shares in a private placement led by new strategic investors. Oppenheimer & Co. Inc. acted as placement agent for the transaction.

The private placement, which is expected to close on or about Aug. 15, is in addition to the $10 million convertible notes issued by the company in May to existing investors.

ChromaDex plans to use the proceeds to expand its product Tru Niagen, also known as nicotinamide riboside, in the international markets.

The product, currently approved in the U.S., boosts the production of nicotinamide adenine dinucleotide, or NAD+, in the body. A decline in NAD is said to play a major role in how humans age.